Top in hem/onc: Coffee and cancer, annual mammography

A recent article published in The New England Journal of Medicine concluded that caffeinated coffee does not appear to increase the risk for certain types of cancer. It was the top story in hematology/oncology last week.

Another top story was about a study that showed annual mammography beginning at age 40 or 41 years reduced the risk for breast cancer mortality and added little to the burden of overdiagnosis.

Read these and more top stories in hematology/oncology below:

Caffeinated coffee consumption ‘clearly’ does not increase cancer risk, studies show

Consumption of caffeinated coffee does not appear to increase the risk for various cancer types, according to a recent review article. Read more.

Yearly mammography beginning at age 40 years may reduce breast cancer mortality

Annual mammography beginning at age 40 or 41 years led to a reduction in breast cancer mortality, according to results of a randomized study in the U.K. published in The Lancet Oncology. Read more.

App estimates risk of delaying cancer treatment during pandemic

As the COVID-19 pandemic continues to impact various aspects of cancer care, oncologists must decide whether to delay treatment or proceed despite the increased risk for infection with the novel coronavirus. Read more.

FDA grants fast track designation to XMT-1536 for ovarian cancer subset

The FDA granted fast track designation to XMT-1536 (Mersana Therapeutics) for the treatment of women with high-grade serous ovarian cancer, according to a press release from the agent’s manufacturer. Read more.

Non-small cell lung cancer mortality rates decline sharply amid advances in treatment

Non-small cell lung cancer mortality decreased substantially among the general U.S. population between 2013 and 2016, according to results of a retrospective study published in The New England Journal of Medicine. Read more.